Seroquel XR (quetiapine fumarate, from AstraZeneca) extended-release tablets have been launched in two new strengths, 50mg and 150mg.  It is indicated for the acute treatment of the depressive episodes associated with bipolar disorder and the manic and mixed episodes associated with bipolar I disorder, as well as the maintenance treatment of bipolar I disorder as adjunctive therapy to lithium or divalproex, which received FDA approval in October 2008.

Seroquel XR is already approved for the acute and maintenance treatment of schizophrenia and is also available in 200mg, 300mg, and 400mg strengths.

For more information call (800) 236-9933 or visit